Pancreatic Cancer Research

ResearcherNorthwell HealthActive in the last 2 years

Aslam M. Ejaz

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-1387-2604; OpenAlex author ID A5070002272. Sources: ClinicalTrials.gov.

Their work

Papers
49 (first author 3, last author 14)
Trials
2 (principal investigator on 2)
Grants
0
Labs led
2
Collaborators
86
Papers, trials and grants by year

2015: 1 paper · 2016: none · 2017: 1 paper · 2018: 2 papers · 2019: 3 papers · 2020: 5 papers · 2021: 6 papers · 2022: 10 papers · 2023: 4 papers, 1 trial · 2024: 5 papers · 2025: 6 papers · 2026: 6 papers, 1 trial

Papers 49

  1. Global Perspectives on Radiotherapy Utilization for Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1007/s12029-026-01600-0↗
  2. Fragmented Care for Pancreatic Cancer Patients at a High-Volume Surgical Center. Last author DOI 10.1016/j.jss.2026.03.035↗
  3. Medical and Surgical Oncologist Collaboration and Long-Term Outcomes Among Patients With Pancreatic Cancer. Last author DOI 10.1016/j.jss.2026.06.023↗
  4. Obstructive Sleep Apnea and Short- and Long-Term Outcomes After Pancreatic Cancer Resection. Last author DOI 10.1016/j.jss.2026.07.043↗
  5. Time Toxicity and End-of-Life Treatment of Metastatic Pancreatic Cancer. Last author DOI 10.1200/op-26-00413↗
  6. Simultaneous resection of pancreatic cancer and liver metastases following total neoadjuvant therapy: A case series and analysis of the National Cancer Databas… Last author DOI 10.14701/ahbps.25-209↗
  7. Factors impacting informed decision-making for patients with pancreatic cancer: a qualitative study. Last author DOI 10.1007/s00520-025-09878-9↗
  8. The impact of neoadjuvant therapy in patients with left-sided resectable pancreatic cancer: an international multicenter study. Co-author DOI 10.1016/j.annonc.2024.12.015↗
  9. ACR Appropriateness Criteria® Screening, Locoregional Assessment, and Surveillance of Pancreatic Ductal Adenocarcinoma: 2025 Update. Co-author DOI 10.1016/j.jacr.2025.08.037↗
  10. Shared-decision making in pancreatic cancer: A scoping review. Last author DOI 10.1016/j.pec.2025.108828↗
  11. Surgical Second Opinion for Pancreatic Cancer Patients. Last author DOI 10.1097/xcs.0000000000001213↗
  12. Textbook Neoadjuvant Experience: Defining a Novel Composite Outcomes Measure for Patients with Pancreatic Cancer Undergoing Neoadjuvant Therapy. Co-author DOI 10.1097/xcs.0000000000001277↗
  13. Evaluating the caregiver experience during neoadjuvant therapy for pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/jso.27558↗
  14. Association between social determinants of health and delayed postoperative adjuvant therapy among patients undergoing resection of pancreatic cancer. Co-author DOI 10.1002/jso.27571↗
  15. A qualitative study of providers' perspectives on cross-institutional care coordination for pancreatic cancer: challenges and opportunities. Last author DOI 10.1186/s12913-024-11483-1↗
  16. Serum MUC5AC Predicts Recurrence in Pancreatic Ductal Adenocarcinoma Patients on Neoadjuvant Chemotherapy Co-author DOI 10.20944/preprints202409.0945.v1↗
  17. Mature MUC5AC Expression in Resected Pancreatic Ductal Adenocarcinoma Predicts Treatment Response and Outcomes. Co-author DOI 10.3390/ijms25169041↗
  18. Impact of early vs late palliative care referrals on healthcare utilization in patients with pancreatic cancer. Last author DOI 10.1007/s00432-023-05113-2↗
  19. Evaluating the Quality of Online Information Regarding Neoadjuvant Therapy for Pancreatic Cancer. Co-author DOI 10.1007/s12029-022-00879-z↗
  20. Utilization of Palliative and Hospice Care Among Pancreatic Cancer Patients at an Academic Center. Last author DOI 10.1016/j.jss.2023.03.014↗
  21. Disparities in NCCN Guideline-Compliant Care for Patients with Early-Stage Pancreatic Adenocarcinoma at Minority-Serving versus Non-Minority-Serving Hospitals. Co-author DOI 10.1245/s10434-023-13230-y↗
  22. Impact of care fragmentation on the outcomes of patients receiving neoadjuvant and adjuvant therapy for pancreatic adenocarcinoma. Co-author DOI 10.1002/jso.26706↗
  23. Rates and Outcomes of Aborted Cancer Surgery among Older Patients with Pancreatic Cancer: a SEER-Medicare Study. Co-author DOI 10.1007/s11605-022-05289-x↗
  24. Comparing Minimally Invasive and Open Pancreaticoduodenectomy for the Treatment of Pancreatic Cancer: a Win Ratio Analysis. Co-author DOI 10.1007/s11605-022-05380-3↗
  25. Patterns of health care utilization among Medicare beneficiaries diagnosed with pancreatic adenocarcinoma. Co-author DOI 10.1016/j.amjsurg.2021.10.027↗
  26. Multi-specialty physician perspectives on barriers and facilitators to the use of neoadjuvant therapy for pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.hpb.2021.10.010↗
  27. Geographic variation in attitudes regarding management of locally advanced pancreatic cancer. Co-author DOI 10.1016/j.sopen.2022.07.007↗
  28. Surgical treatment of hepatic oligometastatic pancreatic ductal adenocarcinoma: An analysis of the National Cancer Database. Last author DOI 10.1016/j.surg.2021.12.029↗
  29. Surgical resection rates after neoadjuvant therapy for localized pancreatic ductal adenocarcinoma: meta-analysis. Co-author DOI 10.1093/bjs/znac354↗
  30. Patient Preferences for Neoadjuvant Therapy in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/mpa.0000000000002083↗
  31. Characterizing the patient experience during neoadjuvant therapy for pancreatic ductal adenocarcinoma: A qualitative study. Co-author DOI 10.4251/wjgo.v14.i6.1175↗
  32. Disparities in Stage-Specific Guideline-Concordant Cancer-Directed Treatment for Patients with Pancreatic Adenocarcinoma. Last author DOI 10.1007/s11605-021-04984-5↗
  33. Association of pre-existing mental illness with all-cause and cancer-specific mortality among Medicare beneficiaries with pancreatic cancer. Co-author DOI 10.1016/j.hpb.2020.08.002↗
  34. Increasing neutrophil-to-lymphocyte ratio following radiation is a poor prognostic factor and directly correlates with splenic radiation dose in pancreatic can… Co-author DOI 10.1016/j.radonc.2021.02.035↗
  35. Comment on "Arterial Resection in Pancreatic Cancer Surgery: Effective After a Learning Curve". First author DOI 10.1097/sla.0000000000004789↗
  36. Impact of Race/Ethnicity and County-Level Vulnerability on Receipt of Surgery Among Older Medicare Beneficiaries With the Diagnosis of Early Pancreatic Cancer. Co-author DOI 10.1245/s10434-021-09911-1↗
  37. Neoadjuvant therapy for pancreatic ductal adenocarcinoma: Opportunities for personalized cancer care. Co-author DOI 10.3748/wjg.v27.i27.4383↗
  38. Assessment of textbook oncologic outcomes following pancreaticoduodenectomy for pancreatic adenocarcinoma. Co-author DOI 10.1002/jso.25861↗
  39. Variations in Healthcare Expenditures Among Medicare Beneficiaries Undergoing Resection of Pancreatic Cancer. Co-author DOI 10.1007/s11605-020-04660-0↗
  40. Pathologic complete response following neoadjuvant therapy for pancreatic ductal adenocarcinoma: defining the incidence, predictors, and outcomes. First author DOI 10.1016/j.hpb.2020.01.013↗
  41. Neoadjuvant Therapy for Resectable and Borderline Resectable Pancreatic Cancer: A Meta-Analysis of Randomized Controlled Trials. Co-author DOI 10.3390/jcm9041129↗
  42. Disparities in the Use of Neoadjuvant Therapy for Resectable Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.6004/jnccn.2019.7380↗
  43. Hospice utilization among Medicare beneficiaries dying from pancreatic cancer. Co-author DOI 10.1002/jso.25623↗
  44. Systematic Review of Surgical and Percutaneous Irreversible Electroporation in the Treatment of Locally Advanced Pancreatic Cancer. Co-author DOI 10.1245/s10434-019-07261-7↗
  45. The Impact of Dedicated Cancer Centers on Outcomes Among Medicare Beneficiaries Undergoing Liver and Pancreatic Cancer Surgery. First author DOI 10.1245/s10434-019-07677-1↗
  46. Pancreaticoduodenectomy and Superior Mesenteric Vein Resection Without Reconstruction for Locally Advanced Pancreatic Cancer. Co-author DOI 10.1007/s11605-018-3684-2↗
  47. Pancreaticoduodenectomy with en bloc vein resection for locally advanced pancreatic cancer: a case series without venous reconstruction. Co-author DOI 10.21037/cco.2018.01.01↗
  48. Pancreaticoduodenectomy for pancreatic cancer: perspective from the United States. Co-author DOI 10.21037/cco.2017.02.01↗
  49. Perioperative Blood Transfusion and the Prognosis of Pancreatic Cancer Surgery: Systematic Review and Meta-analysis. Co-author DOI 10.1245/s10434-015-4823-6↗

Trials 2

  1. GI-06: The Impact of Perioperative Hydrocortisone on Patients Undergoing Partial Pancreatectomy Principal investigator NCT07796997↗
  2. Impact of Total Intravenous Anesthesia Following Cancer Surgery, TIVACS Study Principal investigator NCT04992507↗

Closest collaborators

The 25 strongest of 86 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jordan M. Cloyd · 32 shared papers, 2019–2026 · strength 5.42
  2. Timothy Michael Pawlik · 30 shared papers, 2015–2026 · strength 4.78
  3. Mary E. Dillhoff · 20 shared papers, 2019–2026 · strength 3.26
  4. Patrick L. Quinn · 8 shared papers, 2025–2026 · strength 2.71
  5. Allan Tsung · 13 shared papers, 2019–2022 · strength 1.68
  6. J. Madison Hyer · 8 shared papers, 2019–2025 · strength 1.15
  7. Diamantis I. Tsilimigras · 9 shared papers, 2019–2024 · strength 1.15
  8. McKenzie L. Schaefer · 3 shared papers, 2026 · strength 1.08
  9. Eric David Miller · 5 shared papers, 2021–2026 · strength 0.97
  10. Bradley Norman Reames · 6 shared papers, 2018–2026 · strength 0.96
  11. Zachary J. Brown · 5 shared papers, 2021–2023 · strength 0.89
  12. Anne M. Noonan · 5 shared papers, 2020–2026 · strength 0.83
  13. Ashish Manne · 4 shared papers, 2024–2026 · strength 0.81
  14. Ziyi Zhou · 2 shared papers, 2026 · strength 0.75
  15. Heena P. Santry · 5 shared papers, 2020–2022 · strength 0.69
  16. Ahmad B. Hamad · 4 shared papers, 2021–2022 · strength 0.60
  17. Lena Stevens · 3 shared papers, 2022–2024 · strength 0.58
  18. Shafia Rahman · 3 shared papers, 2024–2026 · strength 0.57
  19. Djhenne M. Dalmacy · 3 shared papers, 2022 · strength 0.55
  20. Anghela Z. Paredes · 5 shared papers, 2019–2021 · strength 0.54
  21. Matthew John Weiss · 4 shared papers, 2018–2022 · strength 0.53
  22. Laith I. Abushahin · 3 shared papers, 2020–2026 · strength 0.52
  23. Jin Peng He · 4 shared papers, 2017–2022 · strength 0.45
  24. Somashekar Gopala Krishna · 2 shared papers, 2022–2025 · strength 0.38
  25. Samantha M. Ruff · 2 shared papers, 2023–2024 · strength 0.36

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.